CSG Sets Up First Western Munitions Production in Ukraine, But Stock Slides as Governance Concerns Mount

Czechoslovak Group licenses 155mm and 105mm shell production to Ukrainian Armor, but shares dive 56% amid opaque derivatives stake in chemical supplier Alzchem.

The Czechoslovak Group (CSG) has become the first Western defense company to manufacture NATO-standard artillery shells on Ukrainian soil, licensing production of 155mm and 105mm rounds to local firm Ukrainian Armor. The move marks a significant industrial shift for a sector that has largely avoided direct manufacturing inside an active war zone. But while the operational news is strong — record order books, rising revenue, and expanding capacity — the company's stock continues to bleed, dragged lower by governance fears over its method of building a stake in a key chemical supplier.

Under the license agreement, Ukrainian Armor handles the shell bodies, filling, and final assembly. CSG contributes more complex components such as propellant charges, fuzes, and primers. Initial annual capacity stands at 100,000 155mm rounds and 50,000 105mm rounds. The group has set a longer-term target of 850,000 heavy artillery shells per year by the end of 2026, with half of that volume expected to come from Ukraine. A new line in Slovakia producing 70,000 shells annually is already running at full speed.

CSG’s push into Ukraine is part of a broader vertical integration strategy. The company is simultaneously extending its reach upstream into raw materials and downstream into fuzes. Last quarter it disclosed a 9.9% direct stake in Alzchem Group, a producer of nitrocellulose — a critical ingredient for propellant charges. But the market’s attention has fixed on an additional layer: total return swaps that bring the group’s effective economic exposure to around 20% of Alzchem voting rights, with contracts running through 2027. These derivatives allow CSG to benefit from Alzchem’s performance without immediately crossing regulatory disclosure thresholds, a tactic that some governance analysts have flagged as opaque. Alzchem management has publicly stated the existing strategy will continue unchanged.

On the output side, CSG has signed two long-term contracts to supply artillery fuzes for large-caliber rounds to European NATO nations. The combined value is in the higher double-digit millions of euros. Production will take place at a new joint venture called Fuchs Electronics Europe, established with South African partner Reunert, and located in Dubnica nad Váhom, Slovakia. The facility will manufacture both mechanical and electronic fuzes, and CSG has indicated it could eventually shift some fuze production to Ukraine as well.

Financially, the group’s momentum remains impressive. First-quarter 2026 revenue rose 13.8% to €1.54 billion, with the order backlog hitting a record €17 billion. An additional €27 billion in projects are under negotiation. Management has kept its full-year guidance intact: revenue between €7.4 billion and €7.6 billion, with an adjusted EBIT margin of 24% to 25%.

Yet the market is unimpressed. CSG shares have tumbled 56% from their January 2026 peak of €36.05, trading at €15.66 as of the latest close. The stock lost 13.3% in the past week alone. Annualized 30-day volatility stands at a staggering 78%, and the relative strength index has fallen to 33.7, near oversold territory. The disconnect between operational strength and market valuation leaves the equity in a speculative zone — one where the company’s strategic boldness on the ground has yet to win over investors watching from afar.